You are here: Industry Insights > ORCHARD THERAPEUTICS

News List

AGC Biologics Manufactures Orchard Therapeutics' Libmeldy contractpharma
January 05, 2021
European Commission approves one-time therapy for early-onset Metachromatic Leukodystrophy, manufactured at AGC's Milan facility.
Orchard Therapeutics, MolMed Extend Gene Therapy Mfg. Pact contractpharma
July 10, 2020
MolMed to support the development and manufacture of vectors and drug products for Orchard’s investigational hematopoietic stem cell (HSC) gene therapies.
Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome firstwordpharma
April 26, 2019
Program on Track for MAA and BLA Regulatory Submissions in 2021
Orchard Therapeutics Presents Two-Year Follow-Up Data Versus Historical Control from Registrational Trial of OTL-101 for the Treatment of ADA-SCID firstwordpharma
February 23, 2019
ADA-SCID is a rare, life-threatening, inherited disease caused by mutations in the ADA gene. Deficiencies of the ADA enzyme leads to dysfunction of cells of the immune system, including B, T and natural killer cells.
Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy b3cnewswire
January 08, 2019
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and ......
Orchard Therapeutics and SIRION Biotech Announce Licensing Agreement to Enhance Gene Therapy Manufacturing Efficiency b3cnewswire
December 17, 2018
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with......
Orchard Therapeutics Announces the Build-out of New Gene Therapy Manufacturing Facility in California b3cnewswire
December 14, 2018
Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening....
Orchard Therapeutics Receives EMA PRIME Designation for OTL-300, an Investigational Lentiviral Gene Therapy for the Treatment of Transfusion-Dependent Beta-Thalassemia b3cnewswire
November 10, 2018
Orchard Therapeutics, a leading commercial-stage biotech company dedicated to transforming the lives of patients with rare diseases through innovative gene therapies, today announced that the European Medicines Agency (EMA) has granted Priority Medicines
Orchard Therapeutics Announces Pricing of Initial Public Offering b3cnewswire
November 10, 2018
J.P. Morgan, Goldman Sachs & Co. LLC and Cowen are acting as joint book-running managers for the offering, and Wedbush PacGrow is acting as co-manager.
Orchard Therapeutics Strengthens Global Commercial Leadership Team with Appointments of Heads of US and EMEA Region Commercial Operations b3cnewswire
November 09, 2018
Boston, Mass., USA and London, UK, November 08, 2018 / B3C newswire / -- Orchard Therapeutics (Nasdaq: ORTX), a leading commercial-stage biotech company dedicated to transforming

Previous page 1 2 3 Next page